💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Ramipril

CHEMBL1168 Phase 4 承認済み Small molecule
Half-Life
13-17 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
416.5 g/mol
LogP
1.4
Phase
4

An ACE inhibitor used to treat high blood pressure, heart failure, and to reduce the risk of cardiovascular events in people with coronary artery disease. It works by relaxing blood vessels and reducing the workload on the heart.

分子量

416.5120 g/mol

LogP

1.40

TPSA

95.90 Ų

リピンスキーの五則

適合

治療領域

Ovarian Cancer Alzheimer's Disease Migraine Systemic Lupus Erythematosus Chronic Kidney Disease Stroke Obesity Type 2 Diabetes Hypertension Breast Cancer Heart Failure Atrial Fibrillation Cardiovascular Disease

薬物分類

C — C - Cardiovascular System

作用機序

Prodrug converted to ramiprilat; ACE inhibitor.

Pharmacokinetics (PK)

Half-Life 13-17 hours

Pharmacodynamics (PD)

機序

Prodrug converted to ramiprilat; ACE inhibitor.

2D構造

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21

                

                

                
                

                    
InChI

                    
InChI=1S/C23H32N2O5/c1-3-30-23(29)18(13-12-16-8-5-4-6-9-16)24-15(2)21(26)25-19-11-7-10-17(19)14-20(25)22(27)28/h4-6,8-9,15,17-20,24H,3,7,10-14H2,1-2H3,(H,27,28)/t15-,17-,18-,19-,20-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C23H32N2O5

                    

                    
                    

                        
HBD / HBA

                        
2 / 6

                    

                    
                    

                        
回転可能結合数

                        
10

                    

                    
                    
                    

                        
重原子数

                        
30

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            ACE (Angiotensin-Converting Enzyme)
                            Inhibitor
                        

                        
                        Primary Target
                        
                    

                    
                    

                        

                            ABCB1 (P-glycoprotein)
                            Substrate
                        

                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Major


                            
                                Ramipril + Lithium Carbonate
                            
                        

                        
                        
Ramipril, an ACE inhibitor, reduces lithium renal clearance through decreased glomerular filtration, leading to potentially toxic lithium accumulation.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Ramipril + Empagliflozin
                            
                        

                        
                        
Combining empagliflozin with an ACE inhibitor such as ramipril can cause additive blood pressure reduction and volume depletion, increasing the risk of hypotension and acute kidney injury.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
よくある質問

                

                    
                    

                        
                        

                            
An ACE inhibitor used to treat high blood pressure, heart failure, and to reduce the risk of cardiovascular events in people with coronary artery disease. It works by relaxing blood vessels and reducing the workload on the heart.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Prodrug converted to ramiprilat; ACE inhibitor.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Ramipril: Half-life: 13-17 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Ramipril is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Atorvastatin
                            Small molecule
                        
                        
                        
                            Amlodipine
                            Small molecule
                        
                        
                        
                            Lisinopril
                            Small molecule
                        
                        
                        
                            Metoprolol
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1168.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5362129.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
医学的免責事項

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.